The first full-cycle production line for the human papillomavirus (HPV) vaccine – from antigen synthesis to the finished dosage form – has been launched in the Kirov Region. The announcement was published on the
website of the Ministry of Industry and Trade of the Russian Federation.
The capacity of the new facility will fully meet the needs of the Russian healthcare system. At the initial stage, the plant will produce at least 600,000 doses of the vaccine per year. Following the launch of the second production site in 2027, annual output is expected to reach 3 million doses, creating potential for future exports.
The domestic vaccine Tsegardex has already received its registration certificate. Studies have confirmed its high efficacy and safety for adults. The total investment in the project amounted to 7.5 billion roubles.
HPV refers to a group of 200 known viruses. According to the World Health Organization (WHO), cancers caused by HPV
can be prevented through prophylactic vaccination.
It is noted that the launch of full-cycle production of the domestic vaccine opens up opportunities to expand the National Immunisation Schedule, which in the long term will help significantly reduce the incidence of HPV-related cancers.
Photo: Boy Wirat / iStock
Самые
актуальные новости стран БРИКС https://tvbrics.com